Tiotropium inhalation capsules

DRUG3 trials

Sponsors

Boehringer Ingelheim

Conditions

AsthmaPulmonary Disease, Chronic Obstructive

Phase 3

12-week Treatment With Inhaled Tiotropium (18 mcg Once Daily) on Lung Function and Static Lung Volumes in Stable, Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) Patients. Correlation to Dyspnoea Scales

CompletedNCT02172378

Boehringer IngelheimPulmonary Disease, Chronic Obstructive

Start: 2000-05-31Updated: 2014-06-24

Effect of Tiotropium on Exercise Tolerance in Patients With Chronic Obstructive Pulmonary Disease (COPD)

CompletedNCT02172300

Boehringer IngelheimPulmonary Disease, Chronic Obstructive

Start: 1999-06-30Updated: 2014-06-24

Phase 4

Efficacy and Safety of Tiotropium in Patients With COPD and Concomitant Diagnosis of Asthma

CompletedNCT00152984

Boehringer IngelheimAsthma, Pulmonary Disease, Chronic Obstructive

Start: 2004-12-31End: 2006-04-30Target: 472Updated: 2017-12-28